MaxCyte

Forecast & Rating6 analysts currently cover MaxCyte, with about 83.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $4.11, about 181.3% upside from the current price of $1.46. Price targets range from $2.43 to $5.00 — a wide spread, showing clear disagreement over just how much MaxCyte can rise. For you, this means most professionals who study MaxCyte closely still see room for the stock to rise. Data as of Oct 15, 2026; for reference only and not investment advice.